Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Related Articles by Review for PubMed (Select 17411092)

1.

Cells lacking DNA topoisomerase II beta are resistant to genistein.

López-Lazaro M, Willmore E, Austin CA.

J Nat Prod. 2007 May;70(5):763-7. Epub 2007 Apr 6.

PMID:
17411092
2.

Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.

Salerno S, Da Settimo F, Taliani S, Simorini F, La Motta C, Fornaciari G, Marini AM.

Curr Med Chem. 2010;17(35):4270-90. Review.

PMID:
20939813
3.
4.

DNA topoisomerase I and II as targets for rational design of new anticancer drugs.

Cummings J, Smyth JF.

Ann Oncol. 1993 Aug;4(7):533-43. Review.

PMID:
8395870
5.

Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.

Valkov NI, Sullivan DM.

Semin Hematol. 1997 Oct;34(4 Suppl 5):48-62. Review.

PMID:
9408961
6.

Topoisomerase II enzymes and mutagenicity.

Ferguson LR, Baguley BC.

Environ Mol Mutagen. 1994;24(4):245-61. Review.

PMID:
7851337
7.

[Pleiotropic resistance associated with topoisomerases].

Riou JF, Pommier Y.

Bull Cancer. 1994 Dec;81 Suppl 2:62s-68s. Review. French.

PMID:
7727861
8.

Emerging DNA topisomerase inhibitors as anticancer drugs.

Denny WA.

Expert Opin Emerg Drugs. 2004 May;9(1):105-33. Review.

PMID:
15155139
9.

Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase.

Bakshi RP, Galande S, Muniyappa K.

Crit Rev Biochem Mol Biol. 2001;36(1):1-37. Review.

PMID:
11256504
10.
11.

Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism.

Schoeffler AJ, Berger JM.

Biochem Soc Trans. 2005 Dec;33(Pt 6):1465-70. Review.

PMID:
16246147
12.

Inhibitors of topoisomerases as anticancer drugs: problems and prospects.

Dwarakanath BS, Khaitan D, Mathur R.

Indian J Exp Biol. 2004 Jul;42(7):649-59. Review.

PMID:
15339028
13.

Dual topoisomerase I/II inhibitors in cancer therapy.

Denny WA, Baguley BC.

Curr Top Med Chem. 2003;3(3):339-53. Review.

PMID:
12570767
14.

Topoisomerase inhibitors as anticancer agents: a patent update.

Khadka DB, Cho WJ.

Expert Opin Ther Pat. 2013 Aug;23(8):1033-56. doi: 10.1517/13543776.2013.790958. Epub 2013 Apr 23. Review.

PMID:
23611704
15.

Origin and evolution of DNA topoisomerases.

Forterre P, Gribaldo S, Gadelle D, Serre MC.

Biochimie. 2007 Apr;89(4):427-46. Epub 2007 Jan 4. Review.

PMID:
17293019
16.

Toward a comprehensive model for induced endoreduplication.

Cortés F, Mateos S, Pastor N, Domínguez I.

Life Sci. 2004 Nov 26;76(2):121-35. Review.

PMID:
15519359
17.

Phylogenomics of type II DNA topoisomerases.

Gadelle D, Filée J, Buhler C, Forterre P.

Bioessays. 2003 Mar;25(3):232-42. Review.

PMID:
12596227
18.

Topoisomerases of kinetoplastid parasites: why so fascinating?

Das BB, Sengupta T, Ganguly A, Majumder HK.

Mol Microbiol. 2006 Nov;62(4):917-27. Epub 2006 Oct 17. Review.

PMID:
17042788
19.

Distribution and biological activities of the flavonoid luteolin.

López-Lázaro M.

Mini Rev Med Chem. 2009 Jan;9(1):31-59. Review.

PMID:
19149659
20.

Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles.

Long BH, Rose WC, Vyas DM, Matson JA, Forenza S.

Curr Med Chem Anticancer Agents. 2002 Mar;2(2):255-66. Review.

PMID:
12678746
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk